Can First-Dose Therapeutic Drug Monitoring Predict the Steady State Area Under the Blood Concentration-Time Curve of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation?

Busulfan has high intra-individual variability and possible time-dependent changes in clearance, which complicates therapeutic drug monitoring (TDM), as first dose sampling may not predict the steady state concentrations. In this study, we aimed to use Bayesian pharmacokinetic parameters estimated f...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdullah Alsultan (Author), Ahmed A. Albassam (Author), Abdullah Alturki (Author), Abdulrahman Alsultan (Author), Mohammed Essa (Author), Bader Almuzzaini (Author), Salman Alfadhel (Author)
Format: Book
Published: Frontiers Media S.A., 2022-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_01e02e4f388742e4b3e37dc8881a8c5d
042 |a dc 
100 1 0 |a Abdullah Alsultan  |e author 
700 1 0 |a Abdullah Alsultan  |e author 
700 1 0 |a Ahmed A. Albassam  |e author 
700 1 0 |a Abdullah Alturki  |e author 
700 1 0 |a Abdulrahman Alsultan  |e author 
700 1 0 |a Abdulrahman Alsultan  |e author 
700 1 0 |a Mohammed Essa  |e author 
700 1 0 |a Mohammed Essa  |e author 
700 1 0 |a Mohammed Essa  |e author 
700 1 0 |a Bader Almuzzaini  |e author 
700 1 0 |a Salman Alfadhel  |e author 
245 0 0 |a Can First-Dose Therapeutic Drug Monitoring Predict the Steady State Area Under the Blood Concentration-Time Curve of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation? 
260 |b Frontiers Media S.A.,   |c 2022-04-01T00:00:00Z. 
500 |a 2296-2360 
500 |a 10.3389/fped.2022.834773 
520 |a Busulfan has high intra-individual variability and possible time-dependent changes in clearance, which complicates therapeutic drug monitoring (TDM), as first dose sampling may not predict the steady state concentrations. In this study, we aimed to use Bayesian pharmacokinetic parameters estimated from the first dose to predict the steady state AUC for busulfan. This observational study was conducted among pediatric patients at King Abdullah Specialist Children's Hospital. From each patient, we collected six blood samples (2, 2.25, 2.5, 3, 4, and 6 h after the start of IV infusion of the first dose). A subset of patients were also sampled at the steady state. First, we modeled the data using only the first dose. The model was used to estimate the empirical Bayesian estimates of clearance for each individual patient, then we used the empirical Bayesian estimates of clearance to predict the AUC0-tau at steady state (i.e., predicted AUC0-tau). Steady state AUC0-tau was also calculated for patients sampled at steady state using the trapezoidal method using raw time concentration data; this was considered the reference AUC0-tau.. Then, we compared the AUC0-tau predicted using the Bayesian approach with the reference AUC0-tau values. We calculated bias and precision to assess predictability. In total we had 33 patients sampled after first dose and at steady state. Using the Bayesian approach to predict the AUC0-tau, bias was −2.8% and precision was 33%. This indicates that first dose concentrations cannot accurately predict steady state busulfan concentrations; therefore, follow-up TDM may be required for optimal dosing. 
546 |a EN 
690 |a busulfan 
690 |a pharmacokinetics 
690 |a TDM (therapeutic drug monitoring) 
690 |a Bayesian pharmacokinetics 
690 |a area under the blood concentration-time curve (AUC) 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pediatrics, Vol 10 (2022) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fped.2022.834773/full 
787 0 |n https://doaj.org/toc/2296-2360 
856 4 1 |u https://doaj.org/article/01e02e4f388742e4b3e37dc8881a8c5d  |z Connect to this object online.